NeuroScientific Biopharmaceuticals Past Earnings Performance
Past criteria checks 3/6
NeuroScientific Biopharmaceuticals's earnings have been declining at an average annual rate of -13.6%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 74.9% per year. NeuroScientific Biopharmaceuticals's return on equity is 20%, and it has net margins of 20.1%.
Key information
-13.6%
Earnings growth rate
2.7%
EPS growth rate
Biotechs Industry Growth | 9.6% |
Revenue growth rate | 74.9% |
Return on equity | 20.0% |
Net Margin | 20.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?
May 25Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Jan 27NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans
Oct 07Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth
Jun 23Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Mar 10We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely
Nov 18Revenue & Expenses BreakdownBeta
How NeuroScientific Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 4 | 1 | 2 | 1 |
30 Sep 23 | 4 | 0 | 2 | 3 |
30 Jun 23 | 5 | -1 | 2 | 4 |
31 Mar 23 | 3 | -4 | 2 | 5 |
31 Dec 22 | 1 | -8 | 3 | 6 |
30 Sep 22 | 1 | -9 | 3 | 7 |
30 Jun 22 | 0 | -10 | 3 | 7 |
31 Mar 22 | 0 | -9 | 3 | 6 |
31 Dec 21 | 1 | -8 | 3 | 5 |
30 Sep 21 | 1 | -5 | 2 | 4 |
30 Jun 21 | 1 | -3 | 2 | 2 |
31 Mar 21 | 0 | -3 | 2 | 2 |
31 Dec 20 | 0 | -2 | 1 | 1 |
30 Sep 20 | 0 | -3 | 1 | 1 |
30 Jun 20 | 0 | -3 | 1 | 1 |
31 Mar 20 | 0 | -3 | 1 | 1 |
31 Dec 19 | 0 | -3 | 1 | 1 |
30 Sep 19 | 0 | -2 | 1 | 1 |
30 Jun 19 | 0 | -2 | 1 | 1 |
31 Mar 19 | 0 | -2 | 1 | 1 |
31 Dec 18 | 0 | -1 | 1 | 0 |
30 Sep 18 | 0 | -1 | 1 | 0 |
30 Jun 18 | 0 | -1 | 1 | 0 |
31 Mar 18 | 0 | -1 | 0 | 0 |
31 Dec 17 | 0 | 0 | 0 | 0 |
30 Sep 17 | 0 | 0 | 0 | 0 |
30 Jun 17 | 0 | 0 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
Quality Earnings: NSB has high quality earnings.
Growing Profit Margin: NSB became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NSB has become profitable over the past 5 years, growing earnings by -13.6% per year.
Accelerating Growth: NSB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NSB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.3%).
Return on Equity
High ROE: NSB's Return on Equity (20%) is considered low.